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Objective: Hyperemesis gravidarum (HG) affects 1% of pregnancies and is potentially harmful for 
mother and foetus. Prealbumin is a marker of nutritional status. We wanted to investigate whether 
prealbumin level was associated with severity and nutritional risks of NVP (nausea and vomiting in 
pregnancy). 
Methods: A case-control study including 92 hospitalized patients with hyperemesis gravidarum and 
32 healthy controls.  Serum Prealbumin was correlated to clinical and biochemical nutritional 
parameters, including 24h recall food-diary.  
Results: HG patients had longer gestational length than controls (median 8.6 versus 7.0 weeks, 
p<0.001). Otherwise, the groups were similar regarding pre-pregnant BMI, parity, proportion of earlier 
pregnancies complicated with HG in and weight at inclusion. The prealbumin levels were significant 
lower in HG versus controls: median 0.19 g/L versus 0.23 g/L (95% CI 0.18-0.20 and 0.19-0.25, 
p<0.001). Compared to the control group HG patients had significantly lower 24h energy intake 
(median 653 kcal versus 1790, p<0.001), larger weight-change at inclusion (median –3 kg versus +1 
kg, p<0.001), higher percentage of ketonuria +3 (69% versus 3% p<0.001) and higher PUQE-score 
(Pregnancy Unique Quantification of Emesis and nausea) median 13, 95% CI 13-14 versus 6, 95% CI 
5-8). Prealbumin level , 24 h caloric and protein intake significantly decreased while weight-loss and 
ketonuria increased across severity of NVP as classified  by the three tiered PUQE-score <6, 7-12 and 
13-15 (all p ≤0.004). Prealbumin level was significantly correlated to 24 h protein intake, Pearson 
Correlation =0.401 (p= 0.001, two-tailed). 















Bakgrunn: Uttalt svangerskapskvalme, Hyperemesis gravidarum (HG),er en tilstand som 
rammer ca. 1% av alle gravide. Ubehandlet kan tilstanden føre til alvorlige væske-
/elektrolyttforstyrrelser og underernæring hos kvinnen. Det kan bli farlig både for mor og 
barn. Prealbumin brukes som markør på underernæring. Vi ønsket å vurdere om prealbumin 
nivå hos gravide samsvarer med alvorlighetsgrad og ernæringsmessige risiko ved 
svangerskapskvalme. 
Metode: En case-kontroll studie blant 92 innlagte pasienter med hyperemesis gravidarum og 
32 friske kontroller. Serum prealbumin ble korrelert til kliniske og biokjemiske ernærings 
parametre, inkludert 24-timers matinntak. 
Resultater: HG pasienter hadde lengre svangerskapslengde enn kontrollene (median 8,6 
versus 7,0 uker, p <0,001). Ellers var gruppene like angående pre-gravid BMI, paritet, andel 
med HG i tidligere svangerskap og vekt ved inklusjon. Prealbuminnivåene var signifikant 
lavere i HG versus kontroller: median 0,19 g / L sammenlignet med 0,23 g / L (95% CI 0,18-
0,20 og 0,19 - 0,25, p<0.001). Sammenlignet med kontrollgruppen hadde HG pasienter 
signifikant lavere 24-timers energiinntak (median 653 kcal versus 1790, p <0,001), større 
vekt-endring ved inklusjon (median -3 kg versus +1 kg, p <0,001) høyere prosentandel av 
ketonuri + 3 (69% versus 3% p <0,001) og høyere SUKK-skår (SvangerskapsUtløst Kvalme 
Kvantifisering) median 13, 95% CI 13-14 versus 6, 95% CI 5-8). Prealbuminnivå, 24-timers 
kalori- og proteininntak sank betydelig mens vekttap og ketonuri økte med økende 
alvorlighetsgrad av svangerskapsutløst kvalme klassifisert som tre kategorier SUKK-skår: <6, 
7-12 og 13-15 (alle p ≤0.004). Prealbuminnivået var signifikant korrelert til 24-timer protein 
inntak, Pearson korrelasjon = 0,401 (p = 0,001, to-sidig). 
Konklusjon: prealbumin-måling validerer at pasienter med alvorlig svangerskapsutløst 
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1.1 Hyperemesis Gravidarum 
1.1.1 Definition and diagnoses 
Hyperemesis gravidarum (HG) is from the Greek hyper-, meaning excessive, and emesis, 
meaning vomiting, and the Latin gravidarum, meaning "pregnant [woman]". Therefore, 
hyperemesis gravidarum means "excessive vomiting of pregnant women". 
Nausea and vomiting in pregnancy (NVP) is a very common condition that accompanies early 
pregnancies of up to 91% of women (1). It is often considered to be a “rite of passage” for 
woman providing reassurance that pregnancy proceeds well (2, 3).  HG is a fairly rare and 
extreme form of NVP, with distinct features and outcomes. HG occurs in 0.3 – 3.6% of 
pregnancies with an average of 1.1% (1).   
A standard definition of HG is based  on the American Council on Pharmacy and Chemistry 
1956 conclusions and was given by Fairweather in 1968 in his review “Nausea and Vomiting 
in Pregnancy”: as an “intractable vomiting and disturbed nutrition, such as alteration of 
electrolyte balance, loss of weight of 5 percent or more, ketosis and acetonuria” (4). However, 
the diagnosis is usually made clinically, based on typical presentation and exclusion of other 
causes of nausea and vomiting in the pregnant woman (5).  
The symptoms of NVP generally occur between 5th and 10th gestational weeks (6, 7) with a 
peak at week 12 (5).  Most women experience relief of symptoms by 20 weeks’ gestation. 
However, 10% to 20% of pregnant women have symptoms of NVP up to the end of the 
pregnancy (5). 
Despite the symptoms of NVP usually resolve spontaneously, the symptoms of HG are severe 
and can affect all aspects of a woman’s life: physical, psychological and social (8, 9). HG is 
the most common reason for hospitalization during the first part of pregnancy (9, 10).  
1.1.2 Aetiology 
The aetiology of NVP and HG is poorly understood (3, 11, 12), although some biological, 
physiological, psychological and sociocultural factors are thought to be contributory factors 
(12). Other theories suggest NVP is the body’s natural mechanism that prevents the intake of 





1.1.3   Risk factors 
Risk factors of HG include female fetal sex, younger maternal age (5), multifetal pregnancy, 
nulliparity, obesity (5, 9, 16), pre-pregnancy body mass index (BMI) less than 18,5 kg/m2 
(underweight) or more than 25 kg/m2 (overweight) (5) , metabolic disturbances, a history of 
HG in a previous pregnancy, trophoblastic disorders, psychological disorders (such as 
anorexia nervosa or bulimia) (9, 16) and lower socioeconomic status. In addition, there is a 
growing evidence that Helicobacter pylori infection is a factor in the development of HG 
(17). 
1.1.4 Challenges for the woman 
1.1.4.1 Changes in quality of life 
Women with HG suffer both mentally and physically (18). Smith et al. showed definitive 
connection of NVP with negative effects on different areas of life (6). Using Quality of Life 
(QOL) data, Lacasse et al. found that QOL for women with moderate to severe NVP (HG) 
was similar to women with myocardial infarction or breast cancer (19). Several studies show a 
definite correlation between HG and poor QOL (6, 8, 20). Moreover, women often feel 
disbelieved by health care professionals and their family members regarding severity of their 
symptoms and how much suffering this condition actually causes (9, 21).  
Many women suffering from HG decide to change their plans for current or future pregnancy. 
Seventy six percent of women with a history of the condition reported modifying their 
reproductive plans; many get a fear of pregnancy (9). A Norwegian 10-year cohort of women 
hospitalized due to HG described 27/558 (5%) of women decided to terminate their pregnancy 
(induced abortion) (22). 
1.1.4.2   Decreased nutritional intake 
Due to both nausea and vomiting, women may suffer from insufficient food and fluid intake 
during their illness. This can lead to dehydration, electrolyte and metabolic imbalance, 
nutritional deterioration, and weight loss (23, 24).  
A South-African study of 20 patients with HG compared to 20 healthy controls  showed that 
mean dietary intake of most of the main nutrients were 50% less than the recommended daily 
intake (RDI), significantly different from the control group’s intake. The majority of the HG 
patients had also suboptimal blood levels of thiamine, riboflavin, vitamin B6, vitamin A and 
retinol-binding protein (25). A Norwegian study of 37 HG women and 31 healthy controls 
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confirmed significantly lower dietary intake of the HG patients as compared to the healthy 
pregnant women (20). 
In a survey of 819 women affected by HG, 26.1% had lost more than 15% of their pre-
pregnancy weight. The women with this large weight-loss had more severe accompanying 
symptoms such as anemia, hypotension, retinal hemorrhage, hematemesis, gallbladder 
dysfunction, retinal failure and liver dysfunction (26).  
One of the most serious complications to poorly treated HG is Wernicke’s encephalopathy. 
This is caused by thiamine deficiency and can lead to permanent neurologic dysfunction and 
even death (27).  
1.1.5 Pregnancy outcomes 
Despite most of the effects of HG are maternal, the pregnancy outcomes may be affected. 
There are both short and long-term risks for the fetus. 
1.1.5.1 Low birth weight 
As demonstrated by a meta-analysis performed by Vennendaal et. al. (28), HG pregnancies 
are associated with increased risk of small for gestational age (SGA) and low birth weight 
(LBW) (<2500 g) babies as well as preterm delivery (<37 weeks gestation). In their research, 
Dodds et al. found that affected women with weight gain of less than 7 kg were more likely to 
deliver SGA babies with LBW or preterm deliveries, compared to women with normal 
pregnancies. However, women with HG, who had a pregnancy weight gain of 7 kg or more, 
had the same risks of LBW, SGA or preterm delivery as healthy women (29). In the 
Norwegian study of 558 HG pregnancies, weight gain <7 kg was an independent risk factor 
for SGA or LBW (22). Thus, it seems justifiable to imply the low catch-up weight gain as the 
cause of the poor perinatal outcomes rather than the nausea and vomiting itself (29). 
LBW increases the risk for health complications in early life and has been found to be related 
to increased risks of adult diseases such as coronary heart disease, hypertension, and type 2 
diabetes (30). LBW was on the second place in the list of causes leading to death in US 
infants in 2006 (31).  
1.1.5.2 Other complications 
Other studies have reported an association between HG and different anomalies including 
undescended testicles, trisomy 21, hip dysplasia, and skeletal or central nervous system 
anomalies. However, in a resent meta-analysis congenital malformations were not statistical 
significantly increased in HG compared to control pregnancies (28). 
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1.1.5.3 Long-term outcomes 
There are few follow-up studies of children whose mothers had HG during pregnancy. Thus it 
is difficult to conclude whether HG affects further life of these children or not. Several 
publications have demonstrated NVP and HG to be associated with decreased rates of 
miscarriages when compared to women without these symptoms (14, 32).  
There is one study reporting that infants of women affected with severe HG (lasting at least 
until third trimester of pregnancy) have colic and irritability more often than infants of women 
with shorter lasting or no HG (33). A survey by Ayyavoo and colleagues shows that offspring 
of women with HG have decreased insulin sensitivity and increased fasting glucose values, 
that could mean these people are at risk for developing diabetes mellitus (34). 
However, a Scandinavian registry-based nested case-control study of 14 805 HG women 
cases concluded that hyperemesis does not seem to increase cancer risk of offspring (35).  
1.1.6 Management of NVP and HG 
All women suffering from NVP and HG should receive advice on managing their symptoms 
by lifestyle and dietary changes, non-pharmacological or pharmacological approaches (36). 
The severity of symptoms is a determinant of treatment of NVP and HG (37). Before starting 
any treatment program, other diseases causing nausea or vomiting should be excluded (24, 
36).  
Identifying HG as the extreme form of symptoms of NVP, management is usually guided by 
the same recommendations and algorithms existing for the treatment of NVP (5).  
1.1.6.1 Dietary and lifestyle strategies 
To our knowledge, there are no studies confirming that changes in lifestyle and diet can 
minimize the symptoms of HG. However, some guidelines based on clinical knowledge are 
developed. According to these guidelines, changes in food and fluid intake and daily routines 
can eliminate the symptoms of mild NVP and to some extent help women with HG achieve an 
increased dietary intake (16, 36, 38). A consumption of small frequent portions of food and 
drinks throughout the day is often recommended (16, 36, 39, 40). Cold drinks between each 
food intake can help to prevent dehydration (36). It is also presumed useful to increase dietary 
fiber intake (36) and eat food low in fat and acids (16). Additionally, electrolyte-replacement 
drinks and oral nutritional supplements are also advised as a mean to maintain electrolyte 
balance and an adequate calorie intake (16, 36, 40). Snacks rich in protein (such as nuts, seeds 
or dairy) can help to balance blood sugar level and calm down stomach acid (36, 41, 42). 
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Replacement of hot spicy food by chilled food can prevent nausea caused by odors (16, 23, 
36). 
The main lifestyle recommendations are to avoid stress and get plenty of sleep and rest (16, 
36, 43). Women diagnosed with HG most often require hospitalization. Although women 
should not be completely isolated from visitors, heavy fragrances (e.g. perfumes or flowers) 
or smelly food should be limited. 
1.1.6.2 Pharmacologic therapies 
Antiemetic drugs are commonly used to reduce the symptoms of NVP. They can be used 
separately or in different combinations (36). 
Pharmacologic treatments include: 
- vitamin B6 (pyridoxine) 
- anthihistamines (dimenhydrinate, diphenhydramine, doxylamine, hydroxyzine, 
meclizine)  
- phenothiazines (prochlorperazine, promethazine) 
- dopamine antagonists (droperidol, metoclopramide, trimethobenzamide)  
- 5-hydroxytryptamine3 receptor antagonists (ondansetron) 
-  glucocorticoids (3, 36) 
Despite medications in general are advised to be used carefully during pregnancy, it is 
considered that the most common antiemetics are safe for mother and fetus. However, the 
Norwegian Health Authorities have recently issued a warning, restricting Metoclopramide use 
to a maximum of 5 days (due to possible  neurological complications for the women) (24). 
Ondansetron is preferably not instituted before 10 weeks of gestation (after organogenesis is 
completed as there are some reports linking this medication to congenital heart defects . 
Corticosteroids has not been studied in sufficiently large and consistent studies to make valid 
meta-analyses regarding effects in HG and thus is presently used as “last resort” (44). 
1.1.6.3 Intravenous therapies 
Due to decreased intake of food and water and excessive loss by vomiting, HG patients are at 
risk of being dehydrated and may experience electrolyte imbalance.  Women who are 
dehydrated and unable to tolerate oral fluids require intravenous fluid therapy (45). Most 
patients respond positive to treatment by intravenous fluids (46).  
Even in cases of significant ketonuria and hyponatremia, a normal saline (0.9 % sodium 
chloride) is preferable to dextrose solution or more concentrated solutions of saline (47).  In 
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order to prevent Wernicke encephalopathy, all women, who have experienced vomiting 
lasting 3 weeks or more, should receive thiamine supplementation to their intravenous 
infusions (47). In cases of hypokalemia, potassium chloride can be added to infusions (45). 
1.1.6.4 Nutritional supplements 
If a woman is not responding to antiemetic treatment and rehydration therapy and have 
persistent weight loss, enteral or parenteral nutrition is required (36, 46, 47). Currently, 
women suffering from HG often do not receive sufficient nutritional attention (48). The focus 
of the treatment is usually in correction of dehydration and electrolyte imbalance, and enteral 
tube feeding is sometimes described as a treatment of last resort (3, 22). 
1.1.6.4.1 Enteral Nutrition 
Enteral nutrition (EN, given as tube feeding) is a way of delivering liquid and feeding through 
the gastrointestinal tract. Enteral nutrition can be given to the patients by nasogastric or 
nasojejunal tube. Enteral nutrition is considered to be more natural and a safer alternative of 
the intravenous nutrition, having none of the serious complications related to central catheters 
(such as thrombosis, infection or pneumothorax)(49). Tube feeding is recommended as first-
line nutritional treatment in pregnancy (3, 39). Some observational studies show that the 
enteral tube feeding can effectively treat dehydration and malnutrition and alleviate nausea 
and vomiting symptoms in HG patients (48).  In a Norwegian 10-year cohort study of 558 
women hospitalized for HG it was found that women treated with EN achieved a reversal of 
their weight loss and during the remaining of the pregnancy gained weight in a similar amount 
as women who received either only intravenous fluid or peripheral parenteral nutrition (22). 
A gastric feeding tube can be inserted through the nose and manually gently be pushed 
forward as the patient actively swallow and thus be brought down to the stomach (ventricle).  
A jejunal feeding tube has to be positioned by gastroscopy to allow for passing the tube 
through the pylorus down to the jejunum (upper part of the intestine) (22).  
Designated enteral nutrition (EN) solution should be delivered continuously by infusion 
pump, starting at a low velocity and gradually increasing until approximately 2 litres is given 
during 24 hours (24). After the patient’s general condition has improved and she handles the 
equipment herself she may continue enteral feeding at home. When the woman has resumed 
normal oral food intake throughout two days, the enteral tube can be removed. If enteral 
feeding does not lead to any improvement and the woman continues to lose weight, parenteral 
nutrition (PN) should be considered (50). 
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1.1.6.4.2 Parenteral Nutrition 
Parenteral nutrition (PN) is feeding a person intravenously, bypassing the usual process of 
eating and food absorption by the gut. The person receives nutritional formulae that contain 
nutrients such as glucose, amino acids, lipids and added vitamins and dietary minerals (51). 
PN is preferable when the woman cannot tolerate food through the gastrointestinal system 
(50). For treatment lasting a short period, a peripheral vein catheter is preferred and can be 
administered in parallel with correction of fluid and electrolyte imbalance and while initiating 
the enteral feeding (24). Due to vulnerability of peripheral veins it is rarely possible to 
achieve the infusion volume aimed for if all nutritional needed should be delivered through a 
peripheral catheter.  Thus, when the treatment is prolonged, total parenteral nutrition (TPN) 
should be delivered through a central vein, either by peripheral inserted central line (PICC-
line) or by central venous catheter (CVC) (51).  
Basically, the parenteral solutions do not contain any micronutrients. Therefore, in order to 
prevent nutritional deficiencies, minerals and vitamins should be added to the parenteral 
solution before infusion (49). 
For those women who do not improve by EN or PN supplements, total parenteral nutrition 
(TPN) might be required (52, 53).  TPN means that most of or all of daily nutritional 
requirements are delivered by the venous route. However, TPN should only be used as a last 
resort when all other treatments have failed, as it can be associated with severe complications 
such as thrombosis, metabolic disturbances and infection (54). 
1.1.6.5 Psychological support 
Many NVP/HG suffers still report lack of support from their health care providers (55). The 
role of psychotherapy for managing HG is not well understood. Psychological therapy is not 
essential but may be suitable for women who are interested and find it helpful. Online support 
groups are also available (5). A study from Iran, including 86 pregnant women with moderate 
NVP found that adding 3 weeks of psychological intervention to a medical therapy gives 
positive therapeutic outcome (56). 
1.1.7 Assessment of the severity of HG 
Good clinical assessment tools can be helpful in the validation of the severity of NVP and 
impact of symptoms. The Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) 
index is a 3-item questionnaire that characterizes the severity of NVP. It is available in 3 
forms in order to evaluate the severity of symptoms during tree different time periods: last 12 
hours, last 24 hours and since the beginning of pregnancy (PUQE, PUQE-24, and modified 
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PUQE respectively) (57, 58). These questionnaires are validated in many countries (58), 
including Norway (20). PUQE-24 questionnaire is translated to Norwegian as Svangerskaps 
Utløst Kvalme Kvantifisering (SUKK). In this study a strong inverse correlation between the 
scores of the PUQE questionnaire and the self-reported food intake and weight gain at 
inclusion for the participating women was demonstrated (20). PUQE-scores of 13 or more is a 
significant indicator for hospitalization and necessity of nutritional status evaluation (59). 
The PUQE-questionnaire also includes one question regarding impact of nausea/vomiting on 
the woman’s general well-being/quality of life. It has been demonstrated that this QOL-item 
is inversely correlated to the PUQE-score (20, 58). Both the PUQE-score and the QOL-score 
demonstrated to normalize after treatment/hospitalization in the Norwegian study (20). 
To further assess the physical and psychosocial impact of HG, another questionnaire, the 
Hyperemesis Impact of Symptoms Questionnaire has been developed and validated but has 
not reached as wide spread use as the PUQE-score. It includes 10 questions about activities of 
daily living and psychosocial stress (21).  
1.2 Nutritional status of pregnant woman 
1.2.1 Energy requirements of pregnant woman 
According to the World Health Organization (WHO) “the energy requirement of pregnant 
woman is the level of energy intake from food that will balance her energy expenditure when 
the woman has a body size and composition and level of physical activity consistent with 
good health, and that will allow for the maintenance of economically necessary and socially 
desirable physical activity. In pregnant woman the energy requirement includes the energy 
needs associated with the deposition of tissues consistent with optimal pregnancy outcome.” 
(60). 
Caloric expenditure is not distributed evenly throughout the pregnancy; it is only slightly 
increased during first trimester but increases significantly in the second and third trimesters 
(61). The total energy cost of pregnancy is considered to be 325 MJ, distributed as 375, 1200, 
1950 kJ/day, for the first, second and third trimesters retrospectively (62). 
Nutritional status is adequate when nutritional and energy requirements are covered by food 
intake (63). The weight of a pregnant woman consists of weight of the mother and the fetus. 




1.2.2 Weight gain recommendations 
At this time the WHO does not have recommendations on total weight gain or rate of weight 
gain during pregnancy. However, the US Institute of Medicine has established guidelines for 
weight gain during pregnancy based on pre-pregnancy BMI (65). Women with low BMI 
<18,5 kg/m2, should gain between  12.7 and 18.2 kg during the pregnancy. Normal weight 
women, with BMI between 18.5 and 24.5 kg/m2, are recommended to gain between 11.4 and 
15.9 kg. Women with overweight, whose BMI is between 25 and 29.9 kg/m2 should gain 6.8 
– 11.4 kg and the obese women with BMI over 30 kg/m2 should gain between 5.0 and 9.1 kg 
during pregnancy (65). Women with HG have doubled their risk of low weight gain during 
pregnancy compared to healthy women (29). 
1.2.3 Nutritional requirements 
Pregnancy is a decisive period when maternal nutrition and lifestyle plays important roles 
(31). An adequate nutritional intake during pregnancy is important to ensure proper growth 
and development for fetus and to promote good maternal health (66).  Despite the old sayings 
that pregnant women should “eat for two”, an intake of  2200 – 2900 kcal/day is 
recommended, that is only about 10 – 15% extra as compared to non-pregnant women (67). 
General increase in calories should be as follows: the first trimester require only 10 kcal extra 
per day; during the second trimester an additional 340 kcal/day are recommended; for the 
third trimester the recommendation is 452 kcal/day (68, 69). However, Nordic Nutrition 
Recommendations 2012 give slightly different figures: 103 kcal, 329 kcal and 537 kcal extra 
for the first, second and third trimesters respectively (70).  
Pregnant women should mostly follow general food recommendations (63, 66), with the 
exceptions to avoid some sorts of food that can contain bacteria or other contaminants (71). 
1.2.4 Recommendations of nutrients 
The recommended balance of energy sources during pregnancy is the same as for non-
pregnant women (72). 
1.2.4.1 Proteins 
Due to extra syntheses of maternal tissues and growth of the fetus, the protein requirement 
rises during pregnancy (61, 69). The daily recommendation for protein is 71 g/day, compared 
to 46 g/day for non-pregnant woman (73). The recommended percent of the energy derived 





In order to prevent ketosis and maintain appropriate blood glucose, it is recommended to 
consume between 135g and 175g carbohydrates per day (69). Recommended E% intake of 
carbohydrates is set to be 46 – 60 E% of total energy intake (74). 
1.2.4.3 Lipids 
There are no daily recommendations of total lipid intake either for pregnant or non-pregnant 
women. Nevertheless, the recommendations for daily intake of the essential poly-unsaturated 
fatty acids are set to be 1.4 g/day for omega-3 and 13 g/day for omega-6 (73). The 
recommended E% intake of fat is between 25 and 40 E% of total energy intake (74). 
1.2.5 Recommendations of micronutrients 
The recommendations of micronutrients, given by the Norwegian Directorate of Health are 
presented in Table 1. The recommended value of some micronutrients for pregnant woman 
are the same as for non-pregnant. These micronutrients are Vitamin D, Vitamin B12, 
Potassium, Magnesium and Iron (74). Although Folate intake recommendation for pregnant 
women is the same as for non-pregnant, the risk of fetal neural tube anomalies are 
significantly increased with insufficient intake, thus routinely daily supplementation of 400µg 
folate is a general recommendation in Norway (74). 
















Table 1 Recommended daily intake (RDI) of micronutrients for pregnant and non-pregnant 
women, given by the Norwegian Directorate of Health (74) 
Micronutrient RDI for pregnant woman  RDI for non-pregnant woman 
(18 – 60 years) 
Vitamin A, RAEa 800 (+14%) 700 
Vitamin D, μg 10 10 
Vitamin E, μ-TEb 10 (+25%) 8 
Thiamin, mg 1.5 (+36%) 1.1 
Riboflavin, mg 1.6 (+23%) 1.3 
Niacin, NEc 17 (+13%) 15 
Vitamin B6, mg 1.4 (+17%) 1.2 
Folate, μg 400 400 
Vitamin B12, μg 2.0 2.0 
Vitamin C, mg 85 (+13%) 75 
Calcium, mg 900 (+12.5%) 800 
Phosphorus, mg 700 (+17%) 600 
Potassium, g 3.1 3.1 
Magnesium, mg 280 280 
Iron, mg 15 15 
Zink, mg 9 (+29%) 7 
Copper, mg 1.0 (+11%) 0.9 
Iodine, μg 175 (+17%) 150 
Selenium, μg 60 (+20%) 50 
a  Retinol activity equivalents (RAE); 1 RAE = 1 μg retinol = 12 μg β-carotene. 
b α-tokoferolequivalents; 1 α-tokoferolequivalent (α-TE) = 1 mg RRR-α-tokoferol 
c Niacinequivalents; 1 niacinequivalent (NE) = 1 mg niacin = 60 mg tryptofan. 
 
 
1.2.6 Assessment of nutritional status 
Nutritional status is always associated with food intake. However, absorption and individual 
metabolism are factors that should be taken into consideration. 
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1.2.6.1 Food-intake quantification 
Different methods and types of questionnaires are used for dietary assessment (75). 
Dietary records: the best result, meaning the most representative for one individual, is 
achieved if all intake of food and drinks is registered consecutively during several days, 
including both weekdays and weekends. The respondent writes down all food and drinks 
he/she consumes during these three – four days, or ticks off a specially designed food form 
(75). Although this method is useful in planned investigations like nutritional surveys, the use 
in the hospital may be less useful. There is also the possibility that the dietary intake is 
influenced by the recording. Another method is a food-intake interview by a designated 
nutritionist, where the respondent’s food intake for two or more days is collected.  As such an 
interview is time consuming and is not applicable for all situations, a 24-hour dietary recall 
can be used. This is a questionnaire, where respondent is asked to remember and write down 
all food and beverages that were consumed during the last 24 hours. Specific tick-off forms 
may be constructed to make the registration easier and pictograms may be added to 
demonstrate different portions/sizes of servings (76). A nutritionist will then be able to 
analyze the information collected and estimate total energy intake as well as macro- and 
micro nutritional composition (76). The disadvantage of this method can be in incorrect 
estimation of portion size or under-/over reporting food consumed. 
Food-frequency questionnaire asks respondents about their usual frequency of consumption 
of particular food. Such forms collects information only about frequency of eaten foods with 
no other details (75). 
1.2.6.2 Physical methods of nutritional status evaluation 
The best method for assessing the adequacy of maternal energy intake is to monitor weight 
change (72).  During pregnancy, the weight will encompass both mother and fetus, but fetal 
growth/weight gain will normally be assessed by measuring uterine growth (symphysis-
fundus measure) or by sonography. 
 BMI is a simple index of weight-for-height that is commonly used to classify underweight, 
overweight and obesity in adults. It is defined as the weight in kilograms divided by the 
square of the height in meters. The normal range of BMI is 18.5 – 24.99 kg/m2 (77). For 
pregnant women BMI before pregnancy must be used for classification.  
Mid upper arm circumference (MUAC) is one more parameter that is often used for detecting 
malnutrition (65). In general, MUAC is considered to be a good indicator of lean mass. 
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Additionally, the study showed that there is an association between small MUAC of mother 
and increased risk of infants with LBW (65). No universal MUAC cut-off points are 
established. Different values of MUAC cut-offs are used for different regions. Nevertheless, it 
is recommended to use a MUAC cut-off <22 cm as an indicator of a LBW risk and as an entry 
criterion for nutritional programs (78). It is however, questionable, how quickly the MUAC 
will change upon low dietary intake. 
1.2.6.3 Laboratory assessment of undernutrition 
Some blood and urine tests can give additional information of the short-term nutritional status 
(63). 
Ketonuria 
One of the markers of undernutrition is ketonuria - a high level of the ketones in the urine 
(79).  Generally, ketonuria occurs when high amounts of fat and fatty acids are metabolized 
and ketone bodies that are not metabolized are excreted in the urine. That can be due to low 
supply of carbohydrates from the diet. In such a hunger state, the body uses fatty acids from 
adipose tissue as an alternative energy source. However, other reasons (diabetes mellitus, 
increased metabolism etc.) can be a cause of a high ketones level (80).  
Prealbumin 
Serum prealbumin level can also be used as a marker of malnutrition. Prealbumin is a protein 
that is produced in the liver and gastrointestinal mucosa (81). Prealbumin composition 
compared to the other  proteins of the body has one of the highest number of essential amino 
acids, that makes it a distinct marker for protein synthesis. If dietary protein is of poor 
biologic value or insufficient in amount, or if total calorie intake is low, dietary amino acids 
must be oxidized as fuel. That decreases synthesis of prealbumin (82). Because the half-life of 
prealbumin is just two days, the serum level reflects rapid changes in visceral protein status 
(83). The normal range of prealbumin in blood for women younger than 50 years is 0.23 – 
0.39 g/L (84).  Lower prealbumin scores mean that a patient is at risk for malnutrition and 
needs careful assessment (82). 
Prealbumin is easily quantified by laboratory instruments available in majority of hospitals 
and is less affected by liver disease than other serum proteins (81). 
To our knowledge, there are few studies about the use of prealbumin as a nutritional marker in 
pregnant women in general and in pregnant women suffering from HG. One study of 30 
pregnant women from 1984 concluded that prealbumin can also be used as a nutritional 
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marker during pregnancy (85). Specific reference values of prealbumin level in blood during 































2 Aims and Hypothesis 
Monitoring of the nutritional status among pregnant women is important to ensure optimal 
conditions for growth and development. Women suffering from HG are known to have poor 
nutritional status (20, 22-25).  Pregnancy is characterized by a number of physiological 
changes leading to changes in many serologic parameters (blood values) (86). That is why 
reference values that are provided for the adult non-pregnant female population are not 
necessarily valid during pregnancy. Biochemical parameters that have been validated for use 
in the assessment of nutritional status during pregnancy are scarce. Especially values during 
first trimester, the period when hyperemesis is most prevalent, are lacking. In line with our 
general effort to heighten awareness of nutritional therapy as an important part of treatment 
for HG patients, we wanted to elucidate different aspects of nutritional status monitoring.  
Our main aim in present study is to investigate if prealbumin level in pregnancy is associated 
with severity and nutritional risks of NVP. 
The secondary aims are: 
 To evaluate if prealbumin level in early pregnancy in healthy women correspond to 
the reference range for non-pregnant women. 
 To analyze if prealbumin level correlates with self-reported dietary intake. 
 To evaluate if prealbumin level correlates with the degree of nausea / vomiting 












3 Methods and materials 
3.1 Study design 
This study was originally designed as a prospective case-control study investigating the 
nutritional intake and nutritional status of women hospitalized with diagnosed HG (cases) as 
compared to healthy pregnant women (controls) included during August 2015 - April 2016. 
To increase number of HG patients with available prealbumin analyses, it was decided to 
include into the analyses the relevant information for HG patients, hospitalized at Haukeland 
University Hospital during 2013 – 2015 included in other research studies (Gastric tube 
feeding study and PUQE-validation study). Information regarding these patients was collected 
from the questionnaires filled out by the participants and from the patients’ hospital cases 
files.  
Nutritional parameters (weight, serum prealbumin and ketonuria) were compared between 
patient and control groups. Nutritional intake was assessed by food diaries.  
3.2 Study population 
A total 125 of pregnant women participated in present study. Of these, 92 were hospitalized 
patients with hyperemesis gravidarum and 32 were healthy controls. 
The HG group: 
Women in the HG group were recruited at the gynecological department of Haukeland 
University Hospital. 
Inclusion criteria 
- Hospitalized due to HG: prolonged nausea and vomiting in pregnancy characterized by at 
least two out of three criteria:  
 dehydration 
 weight loss 
 electrolytes imbalances/ketonuria 
- A pregnancy length of less than 16 weeks. 
Women were invited to participate in the study the first morning after hospital admission. 
Exclusion criteria 




The control group: 
Pregnant women referred to the gynecological outpatient clinic at Haukeland University 
Hospital due to any other reason than NVP.  This could also include women referred for 
pregnancy termination and women investigated for threatening miscarriage. 
Inclusion criteria 
- Healthy viable pregnancy 
- A pregnancy length of less than 16 weeks 
Exclusion criteria 
- Inability to understand and write/read Norwegian 
- PUQE-score of 13 or more 
3.3 Demographic data 
At inclusion, participants were asked to fill out a questionnaire collecting general information 
(Appendix I). These parameters were age, gestational age at inclusion, ethnicity, weight 
before pregnancy, education, number of previous pregnancies with and without HG, number 
of deliveries and number of miscarriages. Gestational age at inclusion was estimated 
according to the last date of menstrual period (a.m Naegele) and confirmed by sonography 
results at the date of inclusion (Crown-rump length (CRL); Terminhjulet) collected from the 
patients’ case files.  
Further, collected background information was compared to a ten-year cohort from 
Haukeland University Hospital (22), including 558 women with HG. 
3.4 Assessment of physical parameters 
During anthropometrical measurements, the participants were wearing light clothing and no 
shoes. Weight was obtained by a scale (kg) and height was measured by stadiometer (cm). 
BMI (kg/m2) was calculated as the weight (m) in kilograms divided by the square of the 
height (h) in meters:  BMI = m/h2.  
3.5 Laboratory assessments 
At inclusion, blood samples and urine specimen were collected from participating women. 
For HG patients these analyses were repeated at the discharge from the hospital.  
Ketonuria 
To determine the presence of the ketones in the urine a rapid urine test was used (Cobas 
Combur 7 Test Strips, Roche Diagnostics Limited, Rotkreuz, Switzerland). This involves 
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dipping a test strip with colored fields into an urine sample for one second. After 60 seconds, 
comparing the subsequent color of the test strip with a color table, the concentration of the 
ketones in the urine is determined. Unchanged color of the test strip means absence of any 
ketones in the urine. Changed color shows the presence of ketones. Intensity of the color 
displays the concentration. Ketonuria measures from 0 to 3+. The test is substantially more 
sensitive for acetoacetic acid (detection limit 5 mg/dL = 0.5 mmol/L) than for acetone 
(detection limit about 40 mg/dL = 7 mmol/L) (87).  
Prealbumin 
Blood samples were used to determine serum prealbumin and C-reactive protein (CRP). CRP 
was analyzed to avoid prealbumin values elevated due to infection. Analyses were performed 
in the routine Laboratory for Clinic Biochemistry, Haukeland University Hospital. 
Serum prealbumin was analysed using an immunoturbidometric assay (CV 5.5%) (Cobas 
Integra 400, Roche Diagnostics Limited, Rotkreuz, Switzerland), that measures increasing 
sample turbidity caused by the formation of insoluble immune complexes when antibody to 
prealbumin is added to the sample (88). 
For CRP analyses, serum was obtained by collecting blood into Vacutainer Tubes with no 
additive (Becton Dickinson). Serum high sensitive-CRP was measured by an 
immunoturbidometric assay run on Roche-Hitachi modular system. 
3.6 Questionnaires and variables 
Information of HG patients’ and control group’s severity of nausea and vomiting (PUQE-
score) and nutritional intake during the last 24 hours were collected by the three-questions 
SUKK-questionnaire (translated to Norwegian version of PUQE-24 questionnaire) and a food 
registration ticking list (Appendix II).  The HG patients filled out the PUQE and 24-hours 
registration questionnaires twice, first when they were admitted to the hospital and secondly 
when they were discharged. The control group filled out questionnaires only once at 
inclusion.  
Question one (Q1) was a question regarding the quantity of hours during the last 24 hours the 
pregnant woman felt nausea. The alternative answers were: not any nausea (1p), nausea less 
than one hour (2p), nausea between two and three hours (3p), nausea between four and six 
hours (4p) and nausea lasting more than six hours (5p). 
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Question two (Q2) was a question regarding the quantity of episodes of vomiting that the 
pregnant woman had experienced during the last 24 hours. The alternative answers were: did 
not vomit at all (1p), vomited one or two times (2p), vomited between three and four times 
(3p), vomited between five and six times (4p) and vomited more than six times (5p). 
Question three (Q3) was a question asking how many times during the last 24 hours the 
pregnant woman retched or had dry heaves without bringing anything up. The alternative 
answers were: did not retch or have dry heaves at all (1p), retched or had dry heaves one to 
two times (2 p), retched or had dry heaves between three and four times (3 p), retched or had 
dry heaves between four or five times (4 p) and retched or had dry heaves over six times (5 p). 
Summarizing the scores of the three PUQE questions (Q1–3), leads to a total PUQE-score 
from 3 to 15 points. Result between 3 and 6 points was defined as mild NVP, 7 – 12 points as 
moderate NVP and patients with scores 13 and above were classified as having severe 
NVP/HG in line with former studies (57). 
3.7 Dietary assessment 
Food and drink intake during the last 24 hours before inclusion was registered retrospectively 
by using of 24-hour food recall questionnaire. HG patients also filled out the same form 
before discharge from the hospital. The assessment was done using a food list form slightly 
simplified from the Norwegian national recommendation for prevention and treatment of 
malnutrition (Appendix III) (89). The form included 38 regular food items and drinks that 
were listed with a normal size portion (e.g. one egg, one piece of bread, one cup of yoghurt 
etc.) (Appendix II). In order to improve the participants’ accuracy in reporting portion sizes, 
an evaluated booklet with photograph series of 13 food items with known portion weight was 
used (Appendix IV, Ungkost 3, edited by Mattilsynet). Participants ticked out consecutively 
how many servings of each item they consumed for breakfast, lunch, dinner and supper 
during the last 24 hours. Foods and beverages not listed in the registry form could be added 
manually. To make the food record as precise as possible, the participants were assisted by 
nutritionist student (Olga Zybkina) or study nurse while filling out the questionnaires.  
3.8 Dietary analysis 
Energy, macronutrients (fat, proteins, carbohydrates and fiber) and micronutrients (vitamins, 
micro and macro elements) were calculated from the reported food intake form using a diet 
planner Kostholdsplanleggeren (kostholdsplanleggeren.no) (90). That is an educational 
calculation program designed to display, calculate and compare the nutritional content of 
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foods, dishes, meals and daily and weekly intake (menus). The program is intended for use in 
diet education, nutrition counseling, and for those who want to evaluate and plan own diet. 
Diet Planner is developed by the Norwegian Directorate of Health and the Norwegian Food 
Safety Authority and is based on The Norwegian Food Composition Table (FCT). FCT 
provides information concerning the nutrient- and energy content of the most commonly 
consumed foods in Norway (91). The FCT’s nutritional values are compiled from chemical 
analyses performed in Norwegian quality-assured laboratories, provided by the industry or 
extrapolated from foreign food composition tables. The FCT is an important tool in 
governmental food policy and management, education and public health promotion and for 
health workers and researchers. The table is also used by the food industry as the basis of 
nutrient declarations and in food production. 
3.9 Power calculation 
In line with a former study assessing differences in PUQE-score and nutritional intake 
between HG and healthy pregnant women it was found that 28 patients in each group 
represent 80% and 100% power to find significant differences (20).  The sample size are 
determined using data from the Canadian study (57) with a mean PUQE-score with 11 +/-3 in 
the HG group and 9.0 +/-2.2 in control group, with an alpha = 5% (two sided) and a power of 
80%. Similarly, using a data of South-African case-control study (25), a sample size of 28 
would give a 100% power to detect differences in nutritional intake. We did not have any 
prealbumin values to estimate from in these studies. However, if we assumed that they were 
equally different between these two groups as PUQE-score and nutritional intake, minimum 
of 30 patients in each group was needed. To achieve this number of HG patients with 
available prealbumin values during the time of inclusion available for this master project, 
information from patients admitted to the department of gynecology during September 2013-
July 2015 was also collected. 
3.10 Statistical analysis 
Statistical analysis of data was performed by using the statistic program IBM SPSS 
(Statistical Package for the Social Sciences) Statistics version 23 (IBM, Armonk, NY, USA). 
Statistical significance was set at p<0.05. All tests were to-sided.  Chi-squared test was used 
to compare categorical variables. The linear variables were compared by non-parametric tests: 
Mann-Whitney U test for two groups, while Kruskal-Wallis test was used for comparing three 
or more groups. Pearson Correlation test was performed for prealbumin concentration in 
blood and protein intake. 
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3.11 Ethical considerations 
The Norwegian Regional Ethical Committee (REK Norway) has approved this study (REK 
2015/894) (Appendix V). The study is registered at ClinicalTrials.gov NCT02619188. 
Additional information regarding the routine prealbumin/ketonuria values from HG patients 
admitted to the department during an earlier study (REK 2013/465) or as a part of a quality 
assessment project evaluating nasogastric tube-feeding (Haukeland Hospital Personal Security 
Officer 2015/8991) has also been included in this evaluation. 
All participants signed consent of participation (Appendix VI). All data were anonymized 
before they were stored electronically on a designated research server in accordance with the 


























During the inclusion period from the 3rd September 2015 to 18th April 2016, 49 women were 
hospitalized due to HG at  Department of  Gynaecology, Haukeland University Hospital. Of 
them, 16 women were included in the study. Thus, participation rate was 33%.  Reasons for 
not joining the study were mainly not being asked to participate due to language difficulties or 
weekend hospitalization (not actively recruiting). Very few women actively declined to 
participate. For one patient food-intake registration is missing. In addition, from the two 
studies 2013-2015 (PUQE evaluation and Gastric tube investigation) data from 76 patients 
was collected retrospectively and included into the analyses. Fourteen of them had filled out 
food-intake questionnaires (in the PUQE-validation study) (20).  
As a control group for the present study, 203 healthy pregnant women were assessed for 
eligibility. Of these, 50 women (25%) agreed to join and filled out PUQE-24 and food intake 
forms and 36 of them completed blood analyses for prealbumin. Four women were excluded 
from the control group due to PUQE-score ≥13. Finally, data from 32 healthy controls was 
analysed.  
The main reasons for not being included was language barrier (not sufficiently reading and 
understanding Norwegian), study person not present at out-patient ward (not actively 
recruiting), age <16 years of age or the woman was not considered sufficient healthy 
psychosocial or physical. Only a minority of women actively declined to participate. 
Thus in total 124 pregnant women participated in present study. Of these, 92 were 
hospitalized patients with hyperemesis gravidarum and 32 healthy controls. The flow of 




 *HG Hyperemesis Gravidarum 
**PUQE Pregnancy unique quantification of emesis and nausea. 
 
 
Figure 1:  Inclusion process, women hospitalized due to HG and healthy control women in 







4.2 Clinical characteristics 
Clinical data for the patients and controls is presented in Table 2. Age, number of pregnancies 
and deliveries, and number of former pregnancies complicated by HG were not significantly 
different between HG and control groups. Physical parameters such as weight before 
pregnancy, weight at inclusion, height and BMI were also not significantly different in two 
groups. Women with HG had a statistical significant longer gestational age (median 8.6 
weeks, 95% CI 8.3-9), compared to the healthy controls (median 7 weeks, 95% CI 6.6-8.1). 
 
 
Table 2 Clinical information from patients hospitalized for HG* and healthy pregnant women 
Variables HG*patients 
n=92 
(Median   95% CI) 
Controls 
n=32 





Age 28 (27 – 30) 26  (22 – 30) 0.127 
Gravidity (number 
pregnancies) 
2 (2 – 2)  1 (1 – 3) 0.209 
Parity 1 (0 – 1) 0 (0 – 1) 0.192 
HG in former pregnancies 
(number)a 
1 (0 – 1) 2 (0 – 3) 0.087 
Weight pre-pregnant (kg)b 66.7 (61.5 - 69.0) 59.0 (54.0 - 67.0) 0.140 
BMIc before pregnancy (kg/m²) 23.5 (22.4 - 24.4) 21.6 (20.1 - 24.5) 0.122 
Weight Inclusion (kg)d 63.9 (58.6 - 68.1) 61.0 (54.0 - 72.0) 0.896 
Height (cm)e 166 (164 - 169) 165 (162 – 170) 0.622 
Gestational length (weeks) 8.6 (8.3 - 9.0) 7.0 (6.6 - 8.1) <0.001 
*Hyperemesis Gravidarum, 
aExcluding nullipara, n=32 in HG* group and n=18 in controls, 
 bPre-pregnant weight missing for five HG patients and one healthy control,  
cBMI: Body Mass Index, information missing for eight HG patients and one healthy control,  
dWeight inclusion missing for two HG patients,  
eHeight missing for four HG patients 
 
4.3 Demographic data of HG patients compared to a 10-years cohort 
Comparing demographic data of the HG group of our study to a former ten-year cohort of 558 
women with HG hospitalized at Haukeland University Hospital (22), we found similar 
background information (Tables 3 - 4).  
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We compared all the HG patients included in our analyses to the historical cohort (Table 3). 
Age, BMI at admission, weight at admission, number of pregnancies and deliveries, 
gestational age and ethnicity were not significantly different compared to the historical cohort. 
More than half of HG patients in both groups (59.7% in historic cohort and 50.6% in present 
study cohort) lost more than 5% of pre-pregnant weight.  
Table 3 Clinical characteristics of historical cohort of patients with hyperemesis gravidarum 
as compared to all present study’s participants with HG 
Variables Historical cohort 
n=558          
Median (Mean) 
Study cohort 
n=92      
Median (Mean) 
P value     
(Mann-Whitney 
U Test) 
Age (years) 28 (28.0) 28 (28.4) 0.474 
BMIa before pregnancy (kg/m2) 23.5 (24.4) 23.6 (23.9) 0.826 
Weight at admission (kg) 61.0 (63.0) 64.9 (64.1) 0.370 
Weight loss (kg) 4.0 (4.2) 3.0 (2.6) 0.002 
Gestational age (weeks) 8.7 (9.5) 8.6 (9.3) 0.608 
 Number (%) Number (%) P value          
Chi-squared test 
Ethnisity    
                Caucasian 412 (73.8%) 53 (65.4%) 
0.112 
                Other 146 (26.2%) 28 (34.6%) 
Gravidity    
                Primigravida 175 (31.4%) 33 (35.5%) 
0.430 
                Multigravida 383 (68.6%) 60 (64.5%) 
Parity    
                Nullipara 240 (43.0%) 46 (41.8%) 
0.817 
                Parous 318 (57%) 64 (58.2%) 
HG in earlier pregnanciesb    
                 No 240 (62.7%) 32 (43.2%) 
0.002 
                 Yes 143 (37.3%) 42 (56.8%) 
Weight loss at admissiona    
        ≤5% of pre pregnant weight 225 (40.3%) 43 (49.4%) 
0.109 
        >5% of pre pregnant weight 333 (59.7%) 44 (50.6%) 
HG: Hyperemesis Gravidarum 
aBMI: Body Mass Index 
bExcluded nullipara, n=383 women in historical cohort and n=14 women in present study. 
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However, there was a statistically significant difference in amount of kilos, lost by the two 
groups’ patients (Historical cohort: median 4.0 kg, present study cohort: median 3.0 kg, p = 
0.002 Mann-Whitney U test). The number of former pregnancies complicated by HG was also 
statistically significantly higher in the combined group of HG patients in present study in 
comparison to historical cohort (56.8% and 37.3% respectively, p = 0.002 Mann-Whitney U 
test). 
Comparing background information of the three groups of HG patients included in our study 
gave us similar results (Table 4). Age, BMI before pregnancy, weight at admission, weight 
loss and gestational age was not statistically significant different between those three groups. 
65% of HG patients were Caucasian (21% of HG patients were of African origin). Among the 
control group, 90% of participants were Caucasian. 
 
Table 4 Clinical characteristics of all groups of present study’s participants with HG 
Variables Study cohort, 
included 
Sept.2015-Apr.2016,   
n=16 
Median (95% CI) 
Study cohort , 
(Gastric tube study) 
included            
Sept.2014-Jun.2015, 
n=62 
Median (95% CI) 
Study cohort,  
(PUQE-validation 
study) included    
Mai 2013 - Jan 2014,   
n=14 




Age (years) 29 (27 – 31) 28 (26 – 30) 26.5 (22 - 23) 0.656 
BMIa before pregnancy 
(kg/m2) 
24.4 (21.5 – 26.7) 23.5 (22.1 – 24.3) 22.8 (20.5 – 26.5) 0.487 
Weight at admissionb (kg) 68.3 (58 – 75.8) 62.0 (56 – 68.1) 57.0 (52 - 75) 0.706 
Weight loss (kg) 2.1 (4.2 – 1.3) 3.6 (4.6 – 2) 3.0 (4.3 - 0) 0.599 
Gestational age (weeks) 8.3 (7.1 – 10.7) 8.5 (8 – 9) 9.3 (7 - 13) 0.455 
aBMI is missing for eight gastric tube study patients  
bWeight is missing for two gastric tube study patients 
HG: Hyperemesis Gravidarum 
PUQE: Pregnancy Unique Quantification of Emesis  
BMI: Body Mass Index 
CI: Confidence Interval 
 
4.4 Nutritional parameters 
All the nutritional parameters were statistically significantly different between HG patients 
and the healthy control group (Table 5). Women with HG had lost median 3 kg (95% CI -4 to 
-2) while the controls had gained median 1 kg (95% CI 0 - 2), this in spite of the control group 
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was included at one week shorter pregnancy duration (Table 1). PUQE-score was statistically 
significantly higher in HG group (median 13, 95% CI 13 - 14, p<0.001 Mann-Whitney U test) 
compared to the healthy controls (median 6, 95% CI 5 - 8). Prealbumin concentration in blood 
was significantly lower among HG patients (median 0.19 g/L 5% CI 0.18 - 0.20, p<0.001 
Mann-Whitney U test) compared to the healthy controls (median 0.23 g/L, 95% CI 0.19 -
0.25). Stem and Leaf plot at Figure 2 demonstrates this difference. Women from the control 
group had no ketonuria (median 0, 95% CI = 0); while in urine of HG patients ketones were 
present at inclusion (median 2+, 95% CI 2 - 3). Caloric and protein intakes estimated in the 
control group were significantly higher (median 1790 kcal, 95% CI 1350 - 2247 and 84g, 95% 
CI 55.3 - 104.1, respectively) as compared to HG group (median 653 kcal, 95% CI 387 - 1066 
and 21.1g, 95% CI 10.6 - 31.2 respectively, all p-values <0.001 Mann-Whitney U test). 
 
 





(Median 95% CI^) 
Controls 
n=32, 





Weight change from pre-
conception to inclusion (kg)a 
-3 
 
(-4 - -2) 1 (0 – 2) <0.001 
PUQE-scoreb 13 (13 – 14) 6 (5 – 8) <0.001 
Prealbumin (g/L) 0.19 (0.18 – 0.20) 0.23 (0.19 – 0.25) <0.001 
Ketonuriac 2 (2 – 3) 0 (0 – 0) <0.001 
24h Caloric intaked (kcal) 653 (387 – 1066) 1790 (1350 – 2247) <0.001 
24h Protein intaked (g) 21.2 (10.6 – 31.2) 84.0 (55.3 – 104.1) <0.001 
*HG: Hyperemesis Gravidarum,  
^CI: Confidence Interval, 
PUQE: Pregnancy Unique Quantification of Emesis, 
aWeight change is missing for 6 HG patients and one healthy control, 
 bPUQE-score is missing for 13 HG patients,  
cKetonuria is missing for 2 HG patients,  






Figure 2: Stem and Leaf plot. Prealbumin concentration (g/L) in blood of Hyperemesis 




4.5 Nutritional parameters compared to severity of NVP/HG 
PUQE-scores can be categorized as to describe three degrees of severity of NVP: low PUQE-
score = Mild NVP with scores between three and six points, moderate PUQE-score = 
moderate NVP with scores between seven and twelve points and high PUQE-score = Severe 
NVP/HG with scores from thirteen to fifteen points (57). This three-tiered PUQE 
categorization correlated significantly with all the major nutritional parameters (Table 6). The 
more severe NVP, the worse nutritional characteristics patients had. Prealbumin level goes 
down, ketonuria rises, weight loss is more pronounced and caloric and protein intake is 









Table 6 Nutritional parameters compared to PUQE-24*-score severity.  
Study of 79 HG patients and 32 healthy pregnant women. 
Variable Mild NVPa 
PUQE-score <7 
n=17 
(Median  95% CI¤) 
Moderate NVP 
 PUQE-score 7-12 
n=40 









Prealbumin (g/L) 0.23 (0.19 – 0.25) 0.20 (0.18 – 0.23) 0.19 (0.18 – 0.20) 0.004 
Ketonuriab 0 (0 – 0) 1 (0 – 2)   2 (2 – 3) <0.001 
Weight change from 
pre-conception to 
inclusion (kg)c 
1 (0 – 3) -1 (-2.6 – 0.8) -4 (-4.4 –  -2.1) <0.001 
Caloric intake 
(kcal/24h)d 
1917 (1531 – 2247) 1194  (834 – 2239) 437 (332 – 871) <0.001 
Protein intake (g/24h) 90.8 (64.6 – 104.1) 47.6  (30.5 – 67) 15.4 (8.3 – 30.9) <0.001 
*PUQE: Pregnancy-Unique Quantification of Emesis and nausea,  
^Hyperemesis Gravidarum,  
¤CI: Confidence Interval; 
aNVP: Nausea and vomiting of pregnancy; 
bKetonuria is missing for 1 patient;  
cWeight change is missing for 6 patients;  
dCaloric and Protein intake is missing for 47 patients. 
 
Scatterplot of prealbumin concentration in blood of the two groups of participants (HG and 








Figure 3: Severity of emesis and nausea in pregnancy measured as PUQE-score 
(Pregnancy Unique Quantification of Emesis and nausea) anticorrelates with serum 




4.6 Nutritional parameters compared to weight change at inclusion 
Comparing nutritional parameters to gross weight change (weight loss, unchanged or gain) of 
all the participants of the study (Table 7), we found that prealbumin level is significantly 
lower in patients with reported weight loss at inclusion (Median 0.19, CI 95% 0.18 – 0.20). 
Similarly, ketonuria is more severe in patients with weight loss (Median 2, CI 95% 2 – 3), as 
compared to those who had weight gain (Median 0, CI 95% 0 – 1). Calculated caloric intake 
and protein intake was statistically significantly different in the three groups (p=0.009 and p= 






Table 7  Nutritional parameters compared to weight change at inclusion.  
Study of 85 HG* patients and 32 healthy pregnant women. 
Variable Weight loss 
n=71 
 
(Median  95% CI^) 
Weight unchanged 
n=13 
(Median  95 % CI) 
Weight gain 
n=33 





Prealbumin (g/L) 0.19 (0.18 – 0.20) 0.20 (0.17 – 0.25) 0.23 (0.19 – 0.24) 0.005 
Ketonuriaa 2 (2 – 3) 0 (0 – 2) 0 (0 – 1) <0.001 
24h Caloric intakeb 
(kcal) 
834 (459 – 1502) 1366 (387 – 2349) 1593 (1253 – 2568) 0.009 
24h Protein 
intakeb (g) 
25.5 (14.9 – 43.5) 38.1 (10.6 – 98.5) 76.5 (52.4 – 106.4) 0.001 
aKetonuria is missing for 1 patient 






4.7 Nutritional intake 
Comparing nutritional intake of two groups of HG patients (PUQE-validation study HG 
patients, and present study HG patients) included in our analyses we have not found 
statistically significant difference in any of these parameters (Table 8). Despite the fact, that 
estimated carbohydrate intake (Median 99.4g, 95% CI 53.9 – 304 in PUQE-validation study 
and median 75.4g, 95% CI 18.5 – 162.4 in present study) and general caloric intake (Median 
719.5 kcal, 95% CI 387 – 1909 and 489 kcal, 95% CI 194 – 1066 in PUQE-validation and 
present studies respectively) seemed to be slightly higher in PUQE-validation study group, a 
non-parametric Mann-Whitney U test showed this to be not significant (p-value = 0.134 both 











Table 8 Comparison of the nutritional intake in the HG* patients recorded 24 hours 
prospectively (PUQE-validation study) and 24 hours retrospectively (present study) 
Variables Study cohort, PUQE^-N 
study, included            
May 2013 – Jan.2014,   
n=14     Median (95% CI¤) 
Study cohort, included 
Sept.2015 – Apr.2016,  
n=15                     





Protein (g) 22 (10.6 – 55.4) 21.2 (4.6 – 31.2) 0.270 
Fat (g) 21.4 (12.4 – 72.6)  17.6 (5.9 – 28.8) 0.186 
Carbohydrates (g) 99.4 (53.9 - 304) 75.4 (18.5 – 162.4) 0.134 
Caloric intake (kcal) 719.5 (387 – 1909) 489 (194 - 1066) 0.134 
*HG: Hyperemesis Gravidarum 
^PUQE: Pregnancy Unique Quantification of Emesis 
¤CI: Confidence Interval 
 
 
Median values of nutrients’ intake, median values of energy percentage of the macronutrients 
and percentage of recommended intake of both macro- and micronutrients are presented in 
Table 9. All nutritional parameters except vitamin C intake were statistically significantly 

















Table 9 Nutritional intake calculated from 24h self-reported food-intake form and percentage 
of daily-recommended intake in the HG* and control groups 
Variables 









Median (95% CI) 
Percent 
of RDI 
Energy (kcal)a 653 (387 - 1066) 27% 1790 (1350 – 2247) 73% <0.001 
Protein (g)b 21.2 (10.6 – 31.2) 30% 84 (55.3  -104.1) 118% <0.001 
Fat (g)c 21 (12.4 – 28.8) - 67.7 (45.9 – 104.8) - <0.001 
Carb’ (g)d 95.4 (54 – 162.3) 62% 193.5 (150.5 – 244.1) 125% 0.001 
Vitamin D (µg) 0.5 (0.3 – 1.0) 5% 2.7 (1.2 – 5.5) 27% 0.001 
Vitamin C (mg) 32.2 (10.5 – 102) 38% 26.5 (10 – 58) 31% 0.465 
Vitamin B12 (µg) 0.6 (0.4 – 1.3) 30% 4.6 (2.3 - 6.2) 230% <0.001 
Calcium (mg) 195 (119.5 – 428) 22% 727 (427 – 1087) 81% 0.001 
Iron (mg) 2.1 (1.3 – 3.3) 14% 8.2 (5.9 – 9.8) 55% <0.001 
Magnesium (mg) 66 (54 – 163) 24% 228 (179 – 322) 81% <0.001 
Sodium (mg) 909 (667 – 1348) 19% 2783 (1573 – 3262) 57% <0.001 
Fiber (g) 5.9 (2.8 – 8.7) 20% 12.5 (8.3 – 18.8) 42% <0.001 
Protein (E%^)e 12 (10 – 14) - 17.5 (16 – 20) - <0.001 
Fat (E%)f 28 (21 – 34) - 36 (33 – 42) - 0.004 
Carb (E%)g 56 (45 – 65) - 47 (41 – 54) - 0.022 
aRecommended energy intake of pregnant women depends among other on their pre-
pregnancy weight and daily level of activity. At present study, the estimated recommended 
level of daily energy intake was set as 2450 kcal. bRecommended protein intake of pregnant 
women is set as 71 g per day (71). cThere are no recommendations on total fat intake per 
day. dRecommended daily intake of carbohydrates is set to be between 135 and 175g per 
day to maintain normal blood glucose (71). Calculated percentage of daily carbohydrate 
intake recommendation is in this case set to the mean of 135 and 175 g: 155g. 
eRecommended protein intake is between 25 and 40 E% of total energy intake (73). 
fRecommended fat intake is between 25 and 45 E% of total energy intake (73). 
gRecommended carbohydrate intake is between 45 and 60 E% of total energy intake (73). 
*HG: Hyperemesis Gravidarum 
¤CI: Confidence interval 
#RDI: Recommended Daily Intake 
^E%: Energy percentage 




4. 8 Energy intake 
The recommended energy intake for healthy pregnant women, set by the Norwegian Health 
board is between 2150 kcal for inactive women and 2400 kcal for active women (74). A cut 
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off was determined as the mean of these values: 2275 kcal. Additionally, for pregnant women 
during the first trimester the daily need is approximately 10 kcal extra per day and in the 
second trimester 340 kcal extra per day (74). 
Comparing the energy intake (kcal) between groups with the three PUQE categories (mild, 
moderate and severe NVP/HG) to the recommended energy intake during the first and the 
second trimester, we found no statistically significant difference in proportion of women with 
sufficient energy intake in the first and the second trimesters (Table 10). However, the results 
shows, that the higher PUQE-score patients have, the larger proportion  have insufficient 
energy intake. Comparing energy intake in the first and the second trimester in the HG group 
to control group, the significant difference was found in the first trimester (Table 11). 
Moreover, the results show that the majority of control group women (75%) and almost all the 
HG patients (97%) have insufficient self-reported energy intake. 
 
Table 10 Sufficient energy intake related to gestational age and PUQE* categories for 29 






3 – 6 
n = 17 
PUQE  
7 – 12 
n = 24 
PUQE  
13 – 15 
n = 20 




Yes 3 5 0 
0.093 
No 13 16 18 
2nd trimesterb 
Yes 0 1 0 
0.549 
No 1 2 2 
aSufficient energy intake for the 1st trimester is estimated as 2285 kcal a day or above. 
bSufficient energy intake for the 2nd trimester is estimated as 2615 kcal a day or above. 
*PUQE: Pregnancy Unique Quantification of Emesis and nausea 









Table 11 Self-reported 24h energy intake in pregnant women, categorized as if meeting 





n = 29 
Control group 
n = 32 




Yes 0 8 
0.007 
No 24 23 
2nd trimesterb 
Yes 1 0 
0.624 
No 4 1 
aSufficient energy intake for the 1st trimester is estimated as 2285 kcal a day or above. 
bSufficient energy intake for the 2nd trimester is estimated as 2615 kcal a day or above. 
*HG: Hyperemesis Gravidarum 
 
 
Table 12 Self-reported 24h energy intake in pregnant women, categorized as if meeting 






n = 29 
Control group 
n = 32 




Yes 1 4 
0.096 
No 18 12 
Normal prealbumin 
(≥0.23 g/L) 
Yes 0 4 
0.086 
No 10 12 
aSufficient energy intake for the 1st trimester is 2285 kcal a day or above. Sufficient energy 
intake for the 2nd trimester is 2615 kcal a day or above. 
*HG: Hyperemesis Gravidarum 
 
 
4.9 Protein intake 
Although, there were not found significant differences in energy intake of HG patients and 
control group with low or normal prealbumin levels (Table 12), statistically significant 
difference in protein intake of both groups appeared (Table 13). 
Prealbumin level was significantly correlated to 24 h protein intake, Pearson Correlation 




Figure 4: Protein intake (g) correlates with serum prealbumin measurements in women with 
Hyperemesis gravidarum (HG) and healthy pregnant controls. 
 
Table 13 Estimated 24h protein intake in pregnant women, categorized as if meeting national 





n = 29 
Control group 
n = 32 




Yes 0 7 
0.001 
No 19 9 
Normal prealbumin 
(≥0.23 g/L) 
Yes 0 10 
0.001 
No 10 6 






This thesis aimed to validate whether serum prealbumin level is associated with severity and 
nutritional risks of nausea and vomiting in pregnancy. Prealbumin levels in blood were 
compared between healthy pregnant women and women hospitalized due to hyperemesis 
gravidarum. We did find that serum prealbumin was significantly lower in HG than healthy 
controls. Prealbumin levels decreased with increased severity of NVP (measured as PUQE-
score) and correlated with self-reported 24h energy- as well as protein intake. 
5.1 Methodological discussion 
5.1.1 Study design and method 
The current study is an observational case-control study where the data from the participants 
was collected using retrospective (last 24 hours)questionnaire forms. Although, randomized 
controlled trials (RCTs) are considered to be the gold standard of the evidence-based medical 
studies evaluating interventions (92, 93), RCTs are not possible to perform for all kinds of 
research or are not always the best choice of a study design because due to ethical reasons 
(94). Our study is not an interventional study but an observational/epidemiologic study where 
RCT is not an option. According to Chang and colleagues, RCTs, prospective cohort studies 
and systematic review of these have high level of evidence (I and II). While retrospective 
studies, case-control studies and systematic review of these have a level of III of evidence 
rating scale (95).  A prospective study thus would be preferable.  
The aim of present study was to evaluate the difference in nutritional parameters of two 
groups of pregnant women: healthy pregnant compared to those whose pregnancy is 
completed with HG. As severe NVP/HG is a relatively rare diagnose, occurring in 1% of 
pregnancies (1), a traditional cohort study would therefore have to be very large (more than 
2800 pregnant women) to meet the estimated number of 28 patients with HG. That is why, a 
case-control study is considered more efficient and realistic to perform within the time period 
available for inclusion.  Nevertheless, because of the slow recruitment of the HG patients at 
the department of gynecology and obstetrics, Haukeland University Hospital, information 
from patients admitted to the department during 2013-july 2015 was also collected. As 
retrospective studies and case-control studies have an equal level of evidence (96), the bias 
between two groups of HG patients we have studied is supposed to be minimal. 
Before starting study enrollment, the nutritional master student was given instructions on how 
to make anthropometrical measurements and take urine test. Training on assisting women in 
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answering food-intake questionnaire to ensure that the food-list was manageable was 
completed before meeting patients. The same food-list had been used in a former study by our 
group (20) and proven to contain relevant food and fluid items. 
5.1.2 Study population 
Each year approximately 50 – 60 women are admitted to Haukeland University Hospital with 
a diagnose HG. Of them, 25% is of non-Caucasian ethnicity and often not Norwegian 
speaking (20). Inclusion period was eight months, leaving an estimate number of 30 women 
with HG and fully able to understand and answer questionnaires in Norwegian.  
We asked our participants about their ethnicity. Despite the fact, that only women able to 
understand Norwegian  were included, only 65% of HG patients were Caucasian (21% of HG 
patients were of African origin). Among the control group, 90% of participants were 
Caucasian. Our results are in line with meta-analyses done by Einarson and colleagues, who 
reported that there were differences in the occurrences of HG in geographic areas (97).  
Additionally, a Norwegian study of variations of prevalence of HG by country of birth stated 
a 3.3 – 3.4 fold higher risk of developing HG in women born in Africa, India and Sri Lanka 
than ethnical Norwegian women (98). 
Both groups (HG and control) were recruited at Haukeland University Hospital; HG  while 
being hospitalized at the gynecological department and controls  while referred to the 
gynecological out-patient clinic. Our PUQE-validation study (20) included healthy controls 
when attending their general practitioner for routine pregnancy care. It was demonstrated in 
that study that healthy pregnant women do not contact health practitioners before the end of 
the first trimester, it is later than hyperemesis patients are usually hospitalized (11.8 and 9 
gestational weeks respectively) (20). To include a control group with a gestational length 
more representative of early/mid first trimester, more in line with when hyperemesis in 
general is diagnosed, it was decided to assess for eligibility also women attending the out-
patient clinic for pregnancy termination consultation. The majority of these patients are 
present their consultation before ninth gestational week. Norwegian women have a 30 % 
lifetime risk to conduct pregnancy termination (99). Pregnancy termination is considered a 
less stigmatizing ”condition” during last years. Norwegian REK has formerly permitted to 
recruit women applying for pregnancy termination for research evaluating blood analyses 
(100). We specifically raised the issue whether it was ethical justifiable to ask this group of 
women to participate with our Regional Ethical Board and got their approval. However, 
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women with psychosocial burdens (such as drug addictions or psychiatric conditions) were 
considered ineligible and would not be asked to participate.   
Thus we managed to enroll a control group of much lower gestational age than the previous 
study (7 weeks, compared to 11.8). Participants with median 8.6 gestational weeks in the HG 
group and 7 gestational weeks in control group, give us a desired cohort representative of 
pregnant women in first trimester. 
Blood test for determination of prealbumin is already a routine test for hospitalized 
hyperemesis patients. Pregnant women, attending the gynecological out-patient clinic (control 
group) will usually have a blood test performed. Thus, some extra vials of blood will not 
present any higher risk for patient.  
The actual participation rate was 33% of hospitalized HG patients and 25% of controls. We 
may have encountered a self-selection bias, as it may be a higher interest in food and health in 
people willing to join the study as compared to the general population (101). Among 
hospitalized women almost none of those who were asked to participate, actually declined. To 
consider if our study cohort is representative for women hospitalized due to HG in general, 
we compared it to a 10-years cohort of HG patients from Department of Gynecology and 
Obstetrics, Haukeland University Hospital (22). Age, BMI at admission, weight at admission, 
number of pregnancies and deliveries, gestational age and ethnicity were not significantly 
different (See Table 3). The HG patients participating in this study had significantly higher 
proportion of women with earlier HG pregnancies (57% as compared to 37% in the historical 
10-year cohort). Thus, women having experienced the debilitating effects of HG possibly are 
more willing to participate in studies regarding that condition. This goes in line with a 
statement that people are more willing to participate in studies investigating disease they have 
(102). 
The participation rate of controls should ideally be higher. Including healthy volunteers for 
studies are always challenging. Taking into account the possible emotional burden of an 
unwanted pregnancy we would definitely avoid these women should feel any pressure to 
participate. In that way a low participation rate is reassuring that those participating really 
consented without any hesitation. By increasing the number of healthy control women per 
women with HG, an increased statistical power of the results could have been achieved (94).  
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To determine a robust reference range for a blood analysis 120 cases are recommended to 
include as a minimum. We did not manage to include this number of healthy pregnant women 
within the inclusion period. 
5.1.3 Collected data 
The women participating in this study have filled out their background information, answered 
the questions regarding the severity of the symptoms of NVP they had (PUQE-form) and 
reported their food and fluid intake during the 24 hours before inclusion. Misclassification 
and false self-reported information can lead to biases in the outcome of the study. However, 
the assistance of the participants in filling out questionnaires by the study personnel should 
raise accuracy of the answers. Generally, women’s answers regarding pregnancy details 
(number of pregnancies, gestational age and previous pregnancy complications such as HG) 
are considered valid. These data is self-reported on the Norwegian pregnancy record 
(Helsekort for gravide) and is a basis for reports to the compulsory Norwegian national birth 
registry (Fødselsregisteret). Pre-pregnant weight was self-reported in our questionnaires, as 
weight at inclusion was measured by study personnel. Overweight women tend to under 
report their actual weight and over report their height, leading to a lower estimated BMI, in 
addition,  underweight women tend to over report their weight. (96). However, the median 
BMI of our participants was 23.5 kg/m2 and 21.6 kg/m2 for HG and control groups 
respectively, that is lower than the cut-off for BMI indicating overweight (25.0 kg/m2).  To 
ensure a correct weight measurement the same scale should have been used before pregnancy 
and at inclusion. Unfortunately, this was not realizable. However to reduce within-group 
variation the same/one weight was used for weighing the HG patients at inclusion (in the 
department) and one weight for all the controls (in the out-patient department). 
Prealbumin blood test and urine tests for ketones were performed using methods that are used 
routinely in Haukeland University Hospital. The prealbumin analyses were performed at the 
laboratory of clinical biochemistry while urine dip-stix analyses were performed by nurses at 
the ward (in-patient or out-patient). 
Prealbumin may be elevated due to concomitant conditions such as infection. To control for 





5.1.4 Estimation of nutritional intake 
For nutritional intake estimation, different methods are available. Data can be collected 
retrospectively (24-hours recall, food frequency questionnaire or diet history) or 
prospectively (estimated diet diary, checklist or weight diet diary). Food intake of any person 
varies from day to day and a 24-hours food recall is not necessarily considered to be 
representative for a person’s mean dietary habits (102). To get a better picture a several days 
food (3 to 7 days) record should be performed and average values calculated (104). However, 
in a study of nutritional intake of 160 women, Bingham and colleagues found, that the 16-
days weight record and food frequency questionnaire were not noticeably better in describing 
individual’s diet than 24–hours questionnaire (103).   
 
The aim of thepresent study was to evaluate correlation between the food intake and PUQE-
score and serum prealbumin level. Serum prealbumin as a nutritional marker has a quite short 
half-life of 2 days (81). That means that changes in diet give rather quick changes in 
prealbumin concentration in blood.  Moreover, PUQE-score is measured by questionnaire, 
evaluating the severity of NVP during the last 24 hours. Thus, a registration of last 24 hours 
food intake is considered to be the most relevant for this particular study.  
 
5.1.5 Dietary assessment 
The food intake was registered using a specially designed tick-off form. The food list 
contained 38 types of regular food and drinks (Appendix II), there were also space to write 
down extra information (types of dinner or desert, topping on bread, etc.). Every participant 
was assisted thoroughly during the filling out of the food-intake form. Special booklet with 
pictures of portion sizes of different foods helped participants to estimate amount of food 
they have eaten. This is an easy way of performing a food registration. We have chosen such 
form of food-registration to achieve more accurate data collection and to get enough 
participants in the two groups for making analyses.  Despite the fact, that booklet with 
portion sizes minimizes mistakes in portion size measurement, miscalculation can occur. 
Sometimes, even photos of different food portion sizes were not sufficient for participants to 
accurately estimate amount of eaten food. In addition, some of the participants might forget 
to register some foods or consciously or unconsciously do not register particular types of 
“unhealthy” food. Women in general  have a tendency to underreport what they have eaten 
(105). Moreover, NVP can differ from day to day and influence food intake. However, in our 
former study (20) we have documented that self-reported food intake anticorrelated with rate 
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of NVP (measured as PUQE-score). Thus, our modified food-frequency chart and the NVP-
questionnaire reporting from the same immediate preceding 24 hours period and related to a 
prealbumin-value taken the morning immediate following this 24-hour period seem a most 
appropriate comparison. 
 
However, given the limitations described, we considered the inclusion of study population 
and methods used as not being significantly biased. Thus, when we found significantly 
differences between the nutritional intake in HG and control groups, this is considered valid. 
 
In general the female population in Bergen/Hordaland is not significantly different form 
those in the rest of Norway. In this regard, we consider our findings to be of relevance for a 
Norwegian pregnant population in general. 
 
5.1.6  Statistical analyses  
The p-value in most test of statistical analyses of present study is lower than 0.001. This 
means, that the statistical significant level is high and the differences between compared 
groups are large. Thus, the chance of type II error is low. Cases with missing data are 















5.2 Discussion of results 
The present study key findings are: 1) serum prealbumin level correlates negatively with 
PUQE-score (the more severe NVP/HG the lower prealbumin concentration in blood was 
measured); 2) nutrient intake of the HG patients is statistically significant lower than the 
nutrient intake of the control group; 3) serum prealbumin level significantly correlated to 24-
hour protein intake; 4) NVP in any grade influence nutritional intake of pregnant women in 
the first trimester (nutritional intake for the majority of HG and control patients is lower than 
recommended values). 
5.2.1 Serum prealbumin level 
Serum prealbumin level of HG group (0.19 g/L) is statistically significant lower than in 
control group (0.23 g/L). However, control group women also have rather low concentration 
of prealbumin in blood. Normal value of serum prealbumin for non-pregnant women 
younger than 50 years is 0.23 – 0.39 g/L (84).  Lower prealbumin scores mean that a patient 
is at risk for malnutrition and needs careful assessment (82). To our knowledge, there are no 
studies about using prealbumin as a nutritional marker during pregnancy, except one from 
1984 (106). That study led the authors to suggest that prealbumin level in blood can be used 
as a nutritional marker in pregnant women as well as in non-pregnant.  Reference values of 
serum prealbumin for pregnant women in the first trimester have not been specifically 
developed. As prealbumin values of 120 healthy pregnant women are needed to robustly 
estimate a normal range of prealbumin concentration in blood for pregnant women in the 
first trimester (107), we did not manage to fulfil this criterion during the time-frame of 
present study.  
5.2.2 Pregnant women in first trimester are at nutritional risk 
According to a previous study from our group (20), PUQE-score correlates inversely to the 
women’s nutritional intake during 24 hours. Our present study also confirms a strong inverse 
correlation between PUQE-score and caloric intake. Compared to the healthy control group, 
statistically significant lower levels of all nutrients except vitamin C are found in the HG 
group. This is in line with what Stuijvenberg and colleagues reported in their study from 
1995 (25), except for their lack of statistically significant difference not only for vitamin C 
but also for vitamin B12 values. Their 24-hours food-intake recall determined 1813 kcal for 
controls and 443 kcal for HG patients. In comparison, our estimations were 1790 kcal and 
653 kcal.  
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Compared to recommended values of energy intake, none of the pregnant women with 
PUQE-score≥13 reached recommended intake of calories.  Moreover, none of the pregnant 
woman in the first trimester diagnose as HG reached recommended values in energy or 
protein intake. The fact, that when woman is actually vomiting, parts of food eaten will be 
not accessible for digestion, leaves the high-score group with even lower actual nutritional 
uptake. Thus, high PUQE-score is compatible with women being at high nutritional risk. As 
a prealbumin level inversely correlates with a PUQE-score, we can consider that it can be 
used as a marker of malnutrition in HG pregnancies. 
The differences in weight changes (patients with the weight loss had the lowest prealbumin 
level, oppositely, patients with weight gain had the highest prealbumin level) strengthen our 
statement of prealbumin being a marker of insufficient nutrition.   
Despite the fact that patients in our HG group have very low caloric intake, 56% of the 
energy they consumed was from carbohydrates. This result supports findings from the 
Mother and Child study that women with severe NVP/HG consume most of their calories 
from carbohydrates (mostly added sugars) (24). Opposite, energy percent from protein intake 
is very low in HG group (12 E%, compared to recommended 25 – 40 E%). However, 
according to food recommendations during pregnancy accomplished by NVP/HG high 
protein intake is recommended. It is suggested that food high in protein may help to reduce 
symptoms of nausea (36, 41). 
The control group of healthy pregnant women had statistically significant higher nutritional 
intake compared to the HG group. Nevertheless, the majority of the control women (75%) 
had insufficient self-reported energy intake as compared to recommended values. Prealbumin 
level in blood of control women is at the lower border of normal range. These facts allow us 
to suggest that the majority of pregnant women, due to NVP during the first trimester, maybe 
more at nutritional risk than generally acknowledged. 
5.3 Conclusion 
This case-control study demonstrated that there was a strong correlation between serum 
prealbumin level and protein/energy intake. Thus, prealbumin measuring can be used to 
identify patients with severe NVP/HG- as being at high nutritional risk. Additionally, we 
found statistically significant differences in all the nutritional parameters between healthy 




 5.4 Future perspectives  
Reference values of prealbumin concentration in blood for pregnant women in the first 
trimester should be developed. A deeper analysis of micronutrients intake can give better 
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